Pertussis vaccine: present status and future prospects.

Area of Science:

• Immunology
• Microbiology
• Vaccinology

Background:

• Killed whole-cell Bordetella pertussis vaccines were effective in controlling symptomatic whooping cough.
• Reduced public confidence in vaccine safety in the UK led to decreased vaccine acceptance and a rise in pertussis incidence.
• There is a need for safer, low-toxicity acellular pertussis vaccines that can prevent both colonization and disease symptoms.

Purpose of the Study:

• To review the role of bacterial components in pertussis pathogenesis for improved vaccine design.
• To discuss the potential of acellular pertussis vaccines utilizing purified adhesins and detoxified pertussis toxin.

Main Methods:

• Literature review on Bordetella pertussis pathogenesis and vaccine development.
• Analysis of bacterial surface components involved in adhesion and systemic effects.
• Discussion of current vaccine design strategies focusing on purified antigens.

Main Results:

• Bordetella pertussis surface components like agglutinogens and filamentous hemagglutinin mediate adhesion to the respiratory mucosa.
• Pertussis toxin (lymphocytosis-promoting factor) is a key factor in the systemic effects of the disease.
• Current vaccine development strategies focus on detoxified pertussis toxin combined with purified adhesins.

Conclusions:

• Understanding the specific roles of bacterial components is crucial for developing effective acellular pertussis vaccines.
• Future vaccines may involve combinations of detoxified pertussis toxin and purified adhesins to enhance efficacy and safety.
• Acellular vaccines aim to provide protection against both colonization and disease symptoms with improved safety profiles.